used 18 myeloid-related features to fit clinical data of patients with HCC and finally constructed a myeloid-specific prognostic signature (based on CD11b and CD169) named myeloid response score (MRS) (8). This evidence concerns the gene SIGLEC1 and hepatocellular carcinoma.